Integrated metabolomics analysis identifies distinct amino acid signatures in chronic hepatitis B patients with metabolic dysfunction-associated steatotic liver disease
Frontiers in Cellular and Infection Microbiology · 2026
DOI: 10.3389/fcimb.2026.1783221 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2026. Verfasst von Yanping Lan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Fujian Key Laboratory of Laboratory Medicine, Gene Diagnosis Research Center, Fujian Clinical Research Center for …. Hauptthemen laut MEDLINE: Amino Acids, Metabolomics, Hepatitis B, Chronic, Fatty Liver. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Fujian Province.
Abstract (Originalsprache)
Background
Chronic hepatitis B (CHB) and metabolic dysfunction-associated steatotic liver disease (MASLD) frequently coexist and synergistically accelerate progression to end-stage liver disease. However, the metabolic differences distinguishing CHB alone from CHB with MASLD remain poorly defined.
Methods
Serum samples from 47 CHB patients with or without MASLD were analyzed as a discovery set using widely targeted metabolomics. An independent validation set of 94 samples was subsequently examined with targeted metabolomics.
Results
CHB patients with MASLD showed marked alterations in amino acid metabolism compared to those with CHB alone. Analysis revealed 206 significantly altered metabolites, among which amino acids represented the largest altered subgroup. Targeted quantification validated nine amino acids significantly upregulated in CHB-MASLD patients: leucine, tryptophan, phenylalanine, tyrosine, glutamic acid, alanine, histidine, lysine, and 2-aminoadipate. These 9 differential amino metabolites (9-DAM) robustly discriminated CHB with MASLD from CHB alone, achieving AUCs of 0.889 and 0.918 in the discovery and validation sets, respectively. The 9-DAM panel consistently outperformed controlled attenuation parameters (CAP) and correlated positively with CAP and liver stiffness measurements.
Conclusions
CHB patients with MASLD exhibit a distinct disruption of circulating amino acid metabolism, reflecting unique metabolomic signatures. These findings highlight promising biomarkers and the pathophysiological significance of this comorbidity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Fujian Key Laboratory of Laboratory Medicine, Gene Diagnosis Research Center, Fujian Clinical Research Center for Clinical Immunology Laboratory Test, The First Affiliated Hospital, Fu…
- Department of Laboratory Medicine, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian, China.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Fujian Province
Zitieren
APA
Lan, Y., Zhou, Z., Huang, Q., Yang, X., Lu, X., Jiang, R., He, Y., Yang, X., Ye, D., Chen, Z., Liu, C., Ou, Q., & Xun, Z. (2026). Integrated metabolomics analysis identifies distinct amino acid signatures in chronic hepatitis B patients with metabolic dysfunction-associated steatotic liver disease. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2026.1783221
Vancouver
Lan Y, Zhou Z, Huang Q, Yang X, Lu X, Jiang R, et al. Integrated metabolomics analysis identifies distinct amino acid signatures in chronic hepatitis B patients with metabolic dysfunction-associated steatotic liver disease. Frontiers in Cellular and Infection Microbiology. 2026. doi:10.3389/fcimb.2026.1783221
BibTeX
@article{Lan2026,
author = {Lan, Yanping and Zhou, Zitao and Huang, Qunfang and Yang, Xin and Lu, Xinrong and Jiang, Renquan and He, Yujue and Yang, Xinyao and Ye, Detai and Chen, Zixin and Liu, Can and Ou, Qishui and Xun, Zhen},
title = {Integrated metabolomics analysis identifies distinct amino acid signatures in chronic hepatitis B patients with metabolic dysfunction-associated steatotic liver disease},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2026},
doi = {10.3389/fcimb.2026.1783221}
}
EUVIMED